GlassScriptPhysician profile
Kenneth Ethan Lai
NPI 1376893974
$3,285.75
in general payments reported to CMS, 2019-2025
17 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $1,475 · 2024: $1,525 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,163.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $529.84 | 2023-2025 | Caplyta |
| Abbvie INC. | $526.26 | 2023-2024 | |
| Corium, LLC | $414.84 | 2023-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $365.83 | 2023-2024 | Ingrezza |
| Organogenesis INC. | $248.53 | 2023 | Affinity, Puraply Antimicrobial |
| Otsuka America Pharmaceutical, INC. | $246.66 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $177.54 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $154.55 | 2023-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $132.38 | 2023-2024 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $126.15 | 2023-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $116.55 | 2023-2024 | Auvelity |
| Ironshore Pharmaceuticals INC. | $98.65 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $56.71 | 2023-2024 | Hetlioz, Fanapt |
| Idorsia Pharmaceuticals US INC | $30.38 | 2023-2024 | Quviviq |
| Tris Pharma INC | $28.52 | 2023-2024 | Dyanavel Xr |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $19.14 | 2024 | Brainsway Deep Tms System |
| Takeda Pharmaceuticals U.S.A., INC. | $13.22 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.